A new manufacturing plant will be built in Japan, at a cost of over $40 million, by Chinese contract development and manufacturing organization (CDMO) Jiuzhou Pharmaceutical.
The new project is aimed at establishing a facility to provide services in the area of research and development, targeting local and global drugmakers.
Jiuzhou already works with a number of global drugmakers, including Gilead Sciences (Nasdaq: GILD), Swiss firms Novartis (NOVN: VX) and Roche (ROG: SIX), as well as a number of Japanese companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze